Microvascular Angina Clinical Trial
— NIRVANAOfficial title:
Nebivolol for the Relief of Microvascular Angina in Women
Women have less significant blockages of coronary arteries, however have greater symptoms and worse outcomes compared to their age-matched male counterparts. This paradox has led to the recognition and importance of the microvasculature ( small vessels) as a contributor to symptoms and outcomes. Nebivolol has unique antioxidant properties and dilates blood vessels and it is therefore proposed that treatment with nebivolol will reduce angina (chest symptoms) in women with microvascular disease as well as improve exercise capacity, reduce resource utilization and improve other measures of artery function.
Status | Completed |
Enrollment | 12 |
Est. completion date | May 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 40 Years to 80 Years |
Eligibility |
Inclusion Criteria: - women between the ages of 40-80 - with evidence of coronary microvascular dysfunction as determined by the presence of rest and or exertional chest tightness and a history of either an elevated troponin level or positive stress test ( EKG criteria or imaging) , as well as non-obstructive coronary artery disease (<50% epicardial obstruction) by either diagnostic catheterization with coronary angiography or CT angiography. Exclusion Criteria: - Women who cannot tolerate a beta blocker. - Women receiving Hormone Replacement Therapy - Women of child-bearing age who are not on a birth-control method. - Women with inability to exercise. - Women with left ventricular systolic dysfunction (LVEF less than 40%) - Women who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial. - Women with any current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If there is a history of such disease but the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included. - Women who are unable to speak, read, and understand English and are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits. - Women with any contraindications to beta blocker therapy - Women with myocardial bridging - Women with Prinzmetal's angina |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Forest Laboratories |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Seattle Angina Questionnaire Score | Seattle Angina Questionnaire (SAQ): The SAQ is a 5 part survey that is widely used and well validated tool to assess angina stability and angina frequency among patients with coronary artery disease. |
3 months | No |
Secondary | peak VO2 measured by cardiopulmonary exercise testing | Assessment of exercise capacity (peak VO2) as determined by CPET, additional fitness parameters will include: VO2 at the anaerobic threshold, peak work-load, time-to-angina, aerobic efficiency and O2 pulse) | 3 months | No |
Secondary | resource utilization questionnaire | Resource utilization as determined by patient phone calls, office visits, emergency room visits, and number of hospitalizations, as well an index cost for any hospitalizations | 3 months | No |
Secondary | SF36 | widely used questionnaire used as a measure of health status will be obtained at baseline ( standardized care ) and follow-up ( 3 months on nebivolol) | baseline and 12 week follow-up | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02147067 -
Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
|
Phase 2 | |
Completed |
NCT06306066 -
Coronary Thermo-dilution Derived Flow-indices in Chronic Coronary Syndrome
|
||
Recruiting |
NCT05288361 -
The DISCOVER INOCA Prospective Multi-center Registry
|
||
Active, not recruiting |
NCT04777045 -
Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial
|
Phase 3 | |
Completed |
NCT04097314 -
Precision Medicine With Zibotentan in Microvascular Angina
|
Phase 2 | |
Recruiting |
NCT06025994 -
Standardizing the Management of Patients With Coronary Microvascular Dysfunction
|
N/A | |
Recruiting |
NCT04598308 -
EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial
|
||
Completed |
NCT03193294 -
CORonary MICrovascular Angina (CorMicA)
|
N/A | |
Not yet recruiting |
NCT02284048 -
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
|
Phase 4 | |
Recruiting |
NCT00921856 -
Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD)
|
N/A | |
Completed |
NCT02602600 -
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
|
Phase 4 | |
Recruiting |
NCT06070662 -
Non-invasive Diagnosis of Coronary Microvascular Disease: Pilot Study
|
||
Terminated |
NCT02914834 -
Acupuncture for Individuals With Stable Angina
|
N/A | |
Completed |
NCT04508998 -
PRIZE ET Sub-Study
|
N/A | |
Recruiting |
NCT05294887 -
Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT02095964 -
HDL-C in Cardiac Syndrome X
|
N/A | |
Recruiting |
NCT06401291 -
Transcutaneous Electrical Nerve Stimulation in Patients With Angina and Non-Obstructive Coronary Arteries
|
N/A | |
Completed |
NCT04391491 -
Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study
|
||
Recruiting |
NCT05635994 -
Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO)
|
||
Recruiting |
NCT05313919 -
Coronary Microcirculatory Disease and Inflammation in Patients With Chronic Coronary Syndrome and no Significant Coronary Artery Stenosis
|